{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:15:30Z","timestamp":1794863730220,"version":"4.9.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Discov"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The alternative splice isoform of pyruvate kinase M (PKM), PKM2, plays a pivotal role in regulating aerobic glycolysis in tumor cells. Systemic delivery of antisense oligonucleotides (ASOs) that shift\n                    <jats:italic>PKM<\/jats:italic>\n                    splicing from the PKM2 isoform to the PKM1 isoform inhibits tumor progression and reprograms intratumoral metabolism. However, the cellular populations within the tumor microenvironment (TME) are also highly dependent on PKM2 and might likewise be affected by ASO treatment. In this study, we demonstrate that PKM2 is upregulated and PKM1 is downregulated in both human and murine pancreatic ductal adenocarcinoma (PDAC) cells. PKM1 and PKM2 are mutually exclusive and expressed in a cell type-specific manner in various cell types and stages of PDAC tumors. We report that basal-like PDAC cells and their surrounding activated regulatory T cells (T\n                    <jats:sub>regs<\/jats:sub>\n                    ) rely on PKM2 to sustain glycolysis. Although PKM-ASO monotherapy had a limited effect in an immunodeficient mouse model of PDAC, synergy between PKM-ASO and anti-CTLA-4 immune checkpoint blockade (ICB), which targets T\n                    <jats:sub>regs<\/jats:sub>\n                    , restricted tumor growth in an immunocompetent mouse model. Our findings provide preclinical support for combined antisense therapy and ICB for PDAC patients, highlighting the critical role of PKM2 in the TME and its potential as a therapeutic target.\n                  <\/jats:p>","DOI":"10.1038\/s41421-026-00882-9","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:04:13Z","timestamp":1776729853000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["ASO-based PKM splice-switching therapy increases anti-CTLA-4 antibody efficacy in pancreatic ductal adenocarcinoma"],"prefix":"10.1038","volume":"12","author":[{"given":"Lijie","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dillon M.","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Danielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0194-1852","authenticated-orcid":false,"given":"Ondrej","family":"Kostov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin H.","family":"Caruthers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9024-9501","authenticated-orcid":false,"given":"Adrian R.","family":"Krainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"882_CR1","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","volume":"38","author":"AS Bear","year":"2020","unstructured":"Bear, A. S., Vonderheide, R. H. & O\u2019Hara, M. H. Challenges and opportunities for pancreatic cancer immunotherapy. Cancer Cell 38, 788\u2013802 (2020).","journal-title":"Cancer Cell"},{"key":"882_CR2","doi-asserted-by":"publisher","DOI":"10.1126\/science.adf6493","volume":"383","author":"MSF Ng","year":"2024","unstructured":"Ng, M. S. F. et al. Deterministic reprogramming of neutrophils within tumors. Science 383, eadf6493 (2024).","journal-title":"Science"},{"key":"882_CR3","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1136\/gutjnl-2021-326070","volume":"72","author":"L Wang","year":"2023","unstructured":"Wang, L. et al. Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment. Gut 72, 958\u2013971 (2023).","journal-title":"Gut"},{"key":"882_CR4","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.immuni.2017.10.017","volume":"47","author":"M Kishore","year":"2017","unstructured":"Kishore, M. et al. Regulatory T cell migration is dependent on glucokinase-mediated glycolysis. Immunity 47, 875\u2013889.e10 (2017).","journal-title":"Immunity"},{"key":"882_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cmet.2018.09.020","volume":"29","author":"L Li","year":"2019","unstructured":"Li, L. et al. TLR8-mediated metabolic control of human Treg function: A mechanistic target for cancer immunotherapy. Cell Metab. 29, 103\u2013123.e5 (2019).","journal-title":"Cell Metab."},{"key":"882_CR6","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adf6717","volume":"8","author":"F Shan","year":"2023","unstructured":"Shan, F. et al. Integrated BATF transcriptional network regulates suppressive intratumoral regulatory T cells. Sci. Immunol. 8, eadf6717 (2023).","journal-title":"Sci. Immunol."},{"key":"882_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","volume":"40","author":"S Kumagai","year":"2022","unstructured":"Kumagai, S. et al. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell 40, 201\u2013218.e9 (2022).","journal-title":"Cancer Cell"},{"key":"882_CR8","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41586-021-03326-4","volume":"591","author":"R Zappasodi","year":"2021","unstructured":"Zappasodi, R. et al. CTLA-4 blockade drives loss of T(reg) stability in glycolysis-low tumours. Nature 591, 652\u2013658 (2021).","journal-title":"Nature"},{"key":"882_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41573-021-00339-6","volume":"21","author":"ZE Stine","year":"2022","unstructured":"Stine, Z. E., Schug, Z. T., Salvino, J. M. & Dang, C. V. Targeting cancer metabolism in the era of precision oncology. Nat. Rev. Drug Discov. 21, 141\u2013162 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"882_CR10","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.15252\/embr.201643300","volume":"17","author":"TL Dayton","year":"2016","unstructured":"Dayton, T. L., Jacks, T. & Vander Heiden, M. G. PKM2, cancer metabolism, and the road ahead. EMBO Rep. 17, 1721\u20131730 (2016).","journal-title":"EMBO Rep."},{"key":"882_CR11","doi-asserted-by":"publisher","first-page":"14366","DOI":"10.1016\/S0021-9258(18)47947-1","volume":"262","author":"T Noguchi","year":"1987","unstructured":"Noguchi, T., Yamada, K., Inoue, H., Matsuda, T. & Tanaka, T. The L- and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters. J. Biol. Chem. 262, 14366\u201314371 (1987).","journal-title":"J. Biol. Chem."},{"key":"882_CR12","doi-asserted-by":"publisher","first-page":"13807","DOI":"10.1016\/S0021-9258(18)67091-7","volume":"261","author":"T Noguchi","year":"1986","unstructured":"Noguchi, T., Inoue, H. & Tanaka, T. The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. J. Biol. Chem. 261, 13807\u201313812 (1986).","journal-title":"J. Biol. Chem."},{"key":"882_CR13","doi-asserted-by":"publisher","first-page":"9417","DOI":"10.1021\/bi0474923","volume":"44","author":"JD Dombrauckas","year":"2005","unstructured":"Dombrauckas, J. D., Santarsiero, B. D. & Mesecar, A. D. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 44, 9417\u20139429 (2005).","journal-title":"Biochemistry"},{"key":"882_CR14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nature06734","volume":"452","author":"HR Christofk","year":"2008","unstructured":"Christofk, H. R. et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230\u2013233 (2008).","journal-title":"Nature"},{"key":"882_CR15","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nchembio.1060","volume":"8","author":"D Anastasiou","year":"2012","unstructured":"Anastasiou, D. et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat. Chem. Biol. 8, 839\u2013847 (2012).","journal-title":"Nat. Chem. Biol."},{"key":"882_CR16","doi-asserted-by":"publisher","first-page":"108345","DOI":"10.1016\/j.jbc.2025.108345","volume":"301","author":"DM Voss","year":"2025","unstructured":"Voss, D. M. et al. PKM splice-switching ASOs induce upregulation of dual-specifi city phosphatases and dephosphorylation of ERK1\/2 in hepatocellular carcinoma. J. Biol. Chem. 301, 108345 (2025).","journal-title":"J. Biol. Chem."},{"key":"882_CR17","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1038\/s41590-024-01963-1","volume":"25","author":"GJ Markowitz","year":"2024","unstructured":"Markowitz, G. J. et al. Deficiency of metabolic regulator PKM2 activates the pentose phosphate pathway and generates TCF1(+) progenitor CD8(+) T cells to improve immunotherapy. Nat. Immunol. 25, 1884\u20131899 (2024).","journal-title":"Nat. Immunol."},{"key":"882_CR18","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.cmet.2025.03.003","volume":"37","author":"SS Mortazavi Farsani","year":"2025","unstructured":"Mortazavi Farsani, S. S. et al. Pyruvate kinase M2 activation reprograms mitochondria in CD8 T cells, enhancing effector functions and efficacy of anti-PD1 therapy. Cell Metab. 37, 1294\u20131310.e7 (2025).","journal-title":"Cell Metab."},{"key":"882_CR19","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ccell.2018.02.004","volume":"33","author":"M Morita","year":"2018","unstructured":"Morita, M. et al. PKM1 confers metabolic advantages and promotes cell-autonomous tumor cell growth. Cancer Cell 33, 355\u2013367.e7 (2018).","journal-title":"Cancer Cell"},{"key":"882_CR20","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1158\/0008-5472.CAN-21-2352","volume":"82","author":"SM Davidson","year":"2022","unstructured":"Davidson, S. M. et al. Pyruvate kinase M1 suppresses development and progression of prostate adenocarcinoma. Cancer Res. 82, 2403\u20132416 (2022).","journal-title":"Cancer Res."},{"key":"882_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.molcel.2014.10.027","volume":"57","author":"SY Lunt","year":"2015","unstructured":"Lunt, S. Y. et al. Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation. Mol. Cell 57, 95\u2013107 (2015).","journal-title":"Mol. Cell"},{"key":"882_CR22","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1158\/0008-5472.CAN-20-0948","volume":"82","author":"WK Ma","year":"2022","unstructured":"Ma, W. K. et al. ASO-based PKM splice-switching therapy inhibits hepatocellular carcinoma growth. Cancer Res. 82, 900\u2013915 (2022).","journal-title":"Cancer Res."},{"key":"882_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47\u201352 (2016).","journal-title":"Nature"},{"key":"882_CR24","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1038\/nbt759","volume":"20","author":"P Sazani","year":"2002","unstructured":"Sazani, P. et al. Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotechnol. 20, 1228\u20131233 (2002).","journal-title":"Nat. Biotechnol."},{"key":"882_CR25","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1089\/nat.2023.0070","volume":"34","author":"L Wan","year":"2024","unstructured":"Wan, L. et al. Screening splice-switching antisense oligonucleotides in pancreas-cancer organoids. Nucleic Acid Ther. 34, 188\u2013198 (2024).","journal-title":"Nucleic Acid Ther."},{"key":"882_CR26","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/ncb2629","volume":"14","author":"W Yang","year":"2012","unstructured":"Yang, W. et al. ERK1\/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat. Cell Biol. 14, 1295\u20131304 (2012).","journal-title":"Nat. Cell Biol."},{"key":"882_CR27","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1038\/onc.2015.270","volume":"35","author":"S Calabretta","year":"2016","unstructured":"Calabretta, S. et al. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells. Oncogene 35, 2031\u20132039 (2016).","journal-title":"Oncogene"},{"key":"882_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40314-w","volume":"14","author":"M Xue","year":"2023","unstructured":"Xue, M. et al. Schwann cells regulate tumor cells and cancer-associated fibroblasts in the pancreatic ductal adenocarcinoma microenvironment. Nat. Commun. 14, 4600 (2023).","journal-title":"Nat. Commun."},{"key":"882_CR29","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","volume":"8","author":"H Tiriac","year":"2018","unstructured":"Tiriac, H. et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 8, 1112\u20131129 (2018).","journal-title":"Cancer Discov."},{"key":"882_CR30","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41577-023-00893-7","volume":"23","author":"JL Trujillo-Ochoa","year":"2023","unstructured":"Trujillo-Ochoa, J. L., Kazemian, M. & Afzali, B. The role of transcription factors in shaping regulatory T cell identity. Nat. Rev. Immunol. 23, 842\u2013856 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"882_CR31","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1158\/2159-8290.CD-20-0569","volume":"11","author":"MZ Madden","year":"2021","unstructured":"Madden, M. Z. & Rathmell, J. C. The complex integration of T-cell metabolism and immunotherapy. Cancer Discov. 11, 1636\u20131643 (2021).","journal-title":"Cancer Discov."},{"key":"882_CR32","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nsmb.2219","volume":"19","author":"M Chen","year":"2012","unstructured":"Chen, M., David, C. J. & Manley, J. L. Concentration-dependent control of pyruvate kinase M mutually exclusive splicing by hnRNP proteins. Nat. Struct. Mol. Biol. 19, 346\u2013354 (2012).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"882_CR33","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig, C. et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. USA 110, 20212\u201320217 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"882_CR34","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","volume":"33","author":"RE Royal","year":"2010","unstructured":"Royal, R. E. et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 33, 828\u2013833 (2010).","journal-title":"J. Immunother."},{"key":"882_CR35","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.gpb.2020.02.005","volume":"19","author":"X Wang","year":"2021","unstructured":"Wang, X., He, Y., Zhang, Q., Ren, X. & Zhang, Z. Direct comparative analyses of 10X Genomics Chromium and Smart-Seq2. Genomics Proteom. Bioinforma. 19, 253\u2013266 (2021).","journal-title":"Genomics Proteom. Bioinforma."},{"key":"882_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40170-018-0188-1","volume":"6","author":"AL Hillis","year":"2018","unstructured":"Hillis, A. L. et al. PKM2 is not required for pancreatic ductal adenocarcinoma. Cancer Metab. 6, 17 (2018).","journal-title":"Cancer Metab."},{"key":"882_CR37","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1158\/0008-5472.CAN-22-1742","volume":"82","author":"KL Pitter","year":"2022","unstructured":"Pitter, K. L. et al. Systematic comparison of pancreatic ductal adenocarcinoma models identifies a conserved highly plastic basal cell state. Cancer Res. 82, 3549\u20133560 (2022).","journal-title":"Cancer Res."},{"key":"882_CR38","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2013.09.025","volume":"155","author":"WJ Israelsen","year":"2013","unstructured":"Israelsen, W. J. et al. PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell 155, 397\u2013409 (2013).","journal-title":"Cell"},{"key":"882_CR39","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1101\/gad.278549.116","volume":"30","author":"TL Dayton","year":"2016","unstructured":"Dayton, T. L. et al. Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma. Genes Dev. 30, 1020\u20131033 (2016).","journal-title":"Genes Dev."},{"key":"882_CR40","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1053\/j.gastro.2012.03.002","volume":"142","author":"PA Perez-Mancera","year":"2012","unstructured":"Perez-Mancera, P. A., Guerra, C., Barbacid, M. & Tuveson, D. A. What we have learned about pancreatic cancer from mouse models. Gastroenterology 142, 1079\u20131092 (2012).","journal-title":"Gastroenterology"},{"key":"882_CR41","doi-asserted-by":"publisher","first-page":"e104104","DOI":"10.1371\/journal.pone.0104104","volume":"9","author":"Y Cao","year":"2014","unstructured":"Cao, Y., Rathmell, J. C. & Macintyre, A. N. Metabolic reprogramming towards aerobic glycolysis correlates with greater proliferative ability and resistance to metabolic inhibition in CD8 versus CD4 T cells. PLoS One 9, e104104 (2014).","journal-title":"PLoS One"},{"key":"882_CR42","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.immuni.2011.09.021","volume":"35","author":"R Wang","year":"2011","unstructured":"Wang, R. et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35, 871\u2013882 (2011).","journal-title":"Immunity"},{"key":"882_CR43","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1038\/s41590-024-01963-1","volume":"25","author":"GJ Markowitz","year":"2024","unstructured":"Markowitz, G. J. et al. Deficiency of metabolic regulator PKM2 activates the pentose phosphate pathway and generates TCF1+ progenitor CD8+ T cells to improve checkpoint blockade. Nat. Immunol. 25, 1884\u20131899 (2024).","journal-title":"Nat. Immunol."},{"key":"882_CR44","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cmet.2019.10.015","volume":"31","author":"S Angiari","year":"2020","unstructured":"Angiari, S. et al. Pharmacological activation of pyruvate kinase M2 inhibits CD4(+) T cell pathogenicity and suppresses autoimmunity. Cell Metab. 31, 391\u2013405.e8 (2020).","journal-title":"Cell Metab."},{"key":"882_CR45","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.cell.2012.07.018","volume":"150","author":"W Yang","year":"2012","unstructured":"Yang, W. et al. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 150, 685\u2013696 (2012).","journal-title":"Cell"},{"key":"882_CR46","doi-asserted-by":"publisher","first-page":"eaay9217","DOI":"10.1126\/scisignal.aay9217","volume":"13","author":"SM Seki","year":"2020","unstructured":"Seki, S. M. et al. Modulation of PKM activity affects the differentiation of T(H)17 cells. Sci. Signal. 13, eaay9217 (2020).","journal-title":"Sci. Signal."},{"key":"882_CR47","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao, Y. et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat. Biotechnol. 42, 293\u2013304 (2024).","journal-title":"Nat. Biotechnol."},{"key":"882_CR48","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen, S., Zhou, Y., Chen, Y. & Gu, J. Fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34, i884\u2013i890 (2018).","journal-title":"Bioinformatics"},{"key":"882_CR49","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1101\/gr.209601.116","volume":"27","author":"T Smith","year":"2017","unstructured":"Smith, T., Heger, A. & Sudbery, I. UMI-tools: modeling sequencing errors in Unique Molecular Identifiers to improve quantification accuracy. Genome Res. 27, 491\u2013499 (2017).","journal-title":"Genome Res."},{"key":"882_CR50","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"882_CR51","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90\u2013W97 (2016).","journal-title":"Nucleic Acids Res."},{"key":"882_CR52","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nbt.2859","volume":"32","author":"C Trapnell","year":"2014","unstructured":"Trapnell, C. et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat. Biotechnol. 32, 381\u2013386 (2014).","journal-title":"Nat. Biotechnol."},{"key":"882_CR53","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1038\/s41596-020-0292-x","volume":"15","author":"M Efremova","year":"2020","unstructured":"Efremova, M., Vento-Tormo, M., Teichmann, S. A. & Vento-Tormo, R. CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes. Nat. Protoc. 15, 1484\u20131506 (2020).","journal-title":"Nat. Protoc."},{"key":"882_CR54","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1038\/s41587-021-00935-2","volume":"39","author":"E Zhao","year":"2021","unstructured":"Zhao, E. et al. Spatial transcriptomics at subspot resolution with BayesSpace. Nat. Biotechnol. 39, 1375\u20131384 (2021).","journal-title":"Nat. Biotechnol."},{"key":"882_CR55","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41587-021-01139-4","volume":"40","author":"V Kleshchevnikov","year":"2022","unstructured":"Kleshchevnikov, V. et al. Cell2location maps fine-grained cell types in spatial transcriptomics. Nat. Biotechnol. 40, 661\u2013671 (2022).","journal-title":"Nat. Biotechnol."},{"key":"882_CR56","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1016\/j.csbj.2021.06.043","volume":"19","author":"M Andreatta","year":"2021","unstructured":"Andreatta, M. & Carmona, S. J. UCell: Robust and scalable single-cell gene signature scoring. Comput Struct. Biotechnol. J. 19, 3796\u20133798 (2021).","journal-title":"Comput Struct. Biotechnol. J."},{"key":"882_CR57","doi-asserted-by":"publisher","first-page":"16240","DOI":"10.1021\/jacs.0c04335","volume":"142","author":"HK Langner","year":"2020","unstructured":"Langner, H. K., Jastrzebska, K. & Caruthers, M. H. Synthesis and characterization of thiophosphoramidate morpholino oligonucleotides and chimeras. J. Am. Chem. Soc. 142, 16240\u201316253 (2020).","journal-title":"J. Am. Chem. Soc."},{"key":"882_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinforma. 12, 323 (2011).","journal-title":"BMC Bioinforma."},{"key":"882_CR59","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/s41596-023-00944-2","volume":"19","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. rMATS-turbo: an efficient and flexible computational tool for alternative splicing analysis of large-scale RNA-seq data. Nat. Protoc. 19, 1083\u20131104 (2024).","journal-title":"Nat. Protoc."},{"key":"882_CR60","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/jmcb\/mjr030","volume":"4","author":"Z Wang","year":"2012","unstructured":"Wang, Z. et al. Exon-centric regulation of pyruvate kinase M alternative splicing via mutually exclusive exons. J. Mol. Cell Biol. 4, 79\u201387 (2012).","journal-title":"J. Mol. Cell Biol."}],"container-title":["Cell Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41421-026-00882-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41421-026-00882-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41421-026-00882-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:04:14Z","timestamp":1776729854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41421-026-00882-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["882"],"URL":"https:\/\/doi.org\/10.1038\/s41421-026-00882-9","relation":{},"ISSN":["2056-5968"],"issn-type":[{"value":"2056-5968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"24 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.R.K. discloses the following commercial relationships, unrelated to the present work: Stoke Therapeutics (Co-Founder and Director); SABs of Inverna Therapeutics, Saturnus Bio, and Autoimmunity BioSolutions; and Consultant for Biogen, SEED Therapeutics, Crucible Therapeutics, Cajal Neuroscience, and Collage Bio. M.H.C. discloses the following commercial interests, unrelated to the current work: ProGenis Therapeutics (Co-Founder and Director), Cirena (Co-Founder and Director), LincSwitch (Director and SAB), SynGenis (Director), SABs of Veranova and Vesicle Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}